-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
PROMISE-2 is a phase 3, randomized, double-blind, placebo-controlled study to evaluate the effects of repeated intravenous (IV) doses of calcitonin gene-related peptide targeting monoclonal antibody eprirenezumab (ALD403) on chronic deviations.
The effectiveness and safety of preventing migraine in adult patients with headache
.
Recently, researchers reported the results of PROMISE-2 treatment for 24 weeks, which has been published in J Headache Pain
prevention
Patients receive up to two 30-minute intravenous injections of 100 mg, 300 mg or placebo, 12 weeks apart
.
Patients recorded the end points of migraine and headache in a daily electronic diary
As a result, a total of 1072 adult patients received treatment: eprinelizumab 100 mg, n = 356; eprinelizumab 300 mg, n = 350; placebo, n = 366
.
During the interval between the first doses, it was observed that the patients’ average monthly migraine days were reduced (100 mg, -7.
In summary, intravenous injection of eprirenizumab 100 mg or 300 mg on day 0 and repeated injections at week 12 can provide continuous migraine prevention effects for a full 24 weeks, and in chronic migraine patients Demonstrate acceptable safety
Original source:
Stephen Silberstein, Merle Diamond, et al.
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study in this message
